Alberto Catalano

Summary

Affiliation: New South Wales
Country: Australia

Publications

  1. ncbi Molecular biology of lymphoma in the microarray era
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Pathology 37:508-22. 2005
  2. ncbi The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
    Blood 110:4073-6. 2007
  3. ncbi All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    Harry J Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Blood 120:1570-80; quiz 1752. 2012
  4. ncbi Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
    Harry Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Haematologica 97:227-34. 2012

Collaborators

  • Lynda J Campbell
  • Andrew Grigg
  • Mark A Dawson
  • Peter Browett
  • Marnie Collins
  • Harry J Iland
  • Juliana Di Iulio
  • John Reynolds
  • Kerry Taylor
  • Ken Bradstock
  • Harry Iland
  • Mark Hertzberg
  • Amanda Hugman
  • John Catalano
  • Campbell Tiley
  • Jeff Szer
  • Juliet Ayling
  • Paul Cannell
  • Michael Seldon
  • Francisca Springall
  • Sandra Deveridge
  • John F Seymour
  • Li Chong
  • Shane Supple
  • John Bashford
  • Noemi Horvath
  • John Seymour
  • John Taper
  • Frank Firkin
  • Tim Brighton
  • Robin Filshie
  • John Moore
  • Shane G Supple

Detail Information

Publications4

  1. ncbi Molecular biology of lymphoma in the microarray era
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Pathology 37:508-22. 2005
    ..Finally, a survey of the current trends in gene expression profiling of lymphomas by microarray technology will be presented with reference to implications for diagnosis, classification, prognosis and treatment...
  2. ncbi The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
    Blood 110:4073-6. 2007
    ..This trial was registered at www.actr.org.au with the Australian Clinical Trials Registry as number 12605000070639...
  3. ncbi All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    Harry J Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Blood 120:1570-80; quiz 1752. 2012
    ..This trial was registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) as ACTRN12605000070639...
  4. ncbi Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
    Harry Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Haematologica 97:227-34. 2012
    ..The role of non-anthracycline drugs in induction and consolidation is less well-established and varies widely between different cooperative group protocols...